Bmab1700
Phase 1Small molecule
Bmab1700 is one of 34 small molecule programs targeting Melanoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Cotellic
RochePhase 3
Nexavar
BayerPhase 3
Alkeran
AApotex Inc.
Phase 3
ABI-007
Bristol-Myers SquibbPhase 3
Lymphoseek
NNavidea Biopharmaceuticals
Phase 3
Anti-PD1
PfizerPhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
IO102-IO103
IIO Biotech
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bmab1700. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBiocon Biologics UK PLC